News
Analyst Coverage
- 14 September 2018 - Bio Shares
- 16 August 2018 - Edison Research Note
- 22 January 2018 - BioWorld
- 6 June 2016 - Bioshares
- 18 April 2016 - Redchip Research Report
- 19 February 2016 - Edison Research Note
- 22 January 2016 - Bioshares
Media Coverage
- 26 March 2019 - OHIO STATE Oncology Update: Novel Anticancer Vaccine Shows Promise in Phase I Study - featuring our Scientific Advisory Board Member Professor Pravin Kaumaya, PhD.
- 7 January 2019 - Your Money - Chairman Paul Hopper interviewed on Trading Day.
- 17 December 2018 - Fierce Biotech - Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer
- 17 December 2018 - SMALL CAPS - Imugene’s Phase 1b HER-Vaxx cancer trial meets endpoints, reports positive results
- 17 December 2018 - STOCKHEAD - Imugene’s gastric cancer drug clears first safety hurdles
- 13 November 2018 - next BIOTECH - Zero Safety Issues for IMU’s Immunotherapy Cancer Treatment: Phase II Trial Imminent
- 31 July 2018 - The Australian Financial Review - Why it’ll pay to be more open to biotech investment opportunities
- 6 June 2018 - The Australian Financial Review - Imugene to raise $20m, fund trials at Ohio State University, Mayo Clinic
- 14 May 2018 - The Australian - Biotech entrepreneur Hopper brings companies to life
- 7 April 2017 - The Australian Financial Review - New thinking answers call of progress
- 5 March 2017 - The Australian Business Review - Imugene CEO Leslie Chong: meet the unicorn leading the cancer fight
- 3 March 2017 - The Sydney Morning Herald - Breakthrough for local biotech as an influential backer emerges
- 22 April 2017 - Bionity.com - HER-Vaxx Re-formation shows dramatic ten-fold increase in Antibodies and early onset of response
- 20 April 2017 - Life Scientist - Imugene candidate increases cancer-fighting antibodies
Company Newsletters
- Newsletter - December 2018
- Newsletter - June 2018
- Newsletter - November 2017
- Newsletter - March 2017
Imugene Videos
- Imugene (ASX: IMU) KEY Vaxx B-cell Peptide Cancer Vaccine Technology 2019, March 5, 2019
- Imugene presenting all three immuno-oncology programs at AACR Annual Meeting, March 3 2019
- Imugene will present lead candidate HER-Vaxx at AACR Annual Meeting, February 27 2019
- Imugene adds key members to its scientific advisory board to advance company forward, January 11 2019
- Infinity Series with Imugene Chairman Paul Hopper ASX: IMU
- Imugene CEO Leslie Chong's Presentation at FNN Investor Event, October 23 2018
- Imugene (ASX:IMU) 1H18 results & outlook
- Imugene (ASX: IMU) Executive Chairman Paul Hopper TV interview on TICKY / YourMoney
- View MD/CEO Leslie Chong being interviewed by Commsec's Tom Piotrowski, June 13 2018
- View MD/CEO Leslie Chong being interviewed by Commsec's Tom Piotrowski, April 6 2018
- View Imugene Immuno-Oncology Expert Briefing featuring Dr Axel Hoos, Prof Dr Christoph Zielinski and Prof Dr Ursula Wiedermann
- CEO Leslie Chong interviewed by Finance News Network in October 2017
- CEO Leslie Chong interviewed by Edison TV in March 2017
Animoca Brands
Arbortech
Blooms the Chemist
Crestone
Federation Alternative Investments
Genex Power
Haoma Mining
Planet Innovation Holdings
PrimaryMarkets
VGW Holdings
Waratah Hotel Group
Sample Trading Hub
Capital Raises
Secondary Trading